Rybelsus (semaglutide oral) / Novo Nordisk 
Welcome,         Profile    Billing    Logout  
 0 Diseases   24 Trials   24 Trials   921 News 


12345678910111213...1920»
  • ||||||||||  Rybelsus (semaglutide oral) / Novo Nordisk, Trulicity (dulaglutide) / Eli Lilly
    Retrospective data, Journal:  Dosing Patterns of Dulaglutide and Semaglutide in Patients with Type (Pubmed Central) -  Jan 30, 2025   
    As oral semaglutide and higher dulaglutide doses are recent to the market, additional real-world evidence is required to evaluate utilization patterns. Graphical abstract available for this article.
  • ||||||||||  Rybelsus (semaglutide oral) / Novo Nordisk
    Journal, Real-world evidence:  Effectiveness of Oral Semaglutide in Management of Type 2 Diabetes: A Real-World Study from India. (Pubmed Central) -  Jan 30, 2025   
    Intensification of existing therapy with Sema-o in obese patients with moderately uncontrolled diabetes proved to be an effective and relatively safe strategy. Achieving normoglycemia and reductions in weight, lipids and body fat/visceral fat with Sema-o may confer a much needed cardiometabolic benefit in these patients.
  • ||||||||||  Rybelsus (semaglutide oral) / Novo Nordisk
    Review, Journal, HEOR, Real-world evidence, Real-world:  Real-world Evidence on Oral Semaglutide for the Management of Type 2 Diabetes. A Narrative Review for Clinical Practice. (Pubmed Central) -  Jan 11, 2025   
    Oral semaglutide constitutes an effective and safe option for T2DM management, and its increased acceptance has the potential to favor the early introduction of GLP-1RAs along the disease course. Nevertheless, continuous evaluation of real-world data is critical to better define the optimal positioning of oral semaglutide along T2DM trajectory and fully exploit its potential in everyday clinical practice.
  • ||||||||||  Enrollment open, Phase classification, Trial completion date, Trial primary completion date:  Steno1: Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 Diabetes (clinicaltrials.gov) -  Jan 10, 2025   
    P3,  N=2000, Recruiting, 
    Nevertheless, continuous evaluation of real-world data is critical to better define the optimal positioning of oral semaglutide along T2DM trajectory and fully exploit its potential in everyday clinical practice. Not yet recruiting --> Recruiting | Phase classification: PN/A --> P3 | Trial completion date: Jan 2030 --> Jul 2029 | Trial primary completion date: Feb 2029 --> Jul 2029
  • ||||||||||  Rybelsus (semaglutide oral) / Novo Nordisk
    Journal, Real-world evidence, Real-world:  Comparing medication persistence with oral and subcutaneous semaglutide in a real-world setting. (Pubmed Central) -  Dec 16, 2024   
    Oral semaglutide reduced HbA1c levels and BW after adding or switching from other incretin-related drugs in Japanese participants with type 2 diabetes. The present real-world study suggests that persistence is significantly lower when semaglutide is administered as a once-daily tablet compared with a weekly injection, while there are no differences in efficacy between the two formulations.
  • ||||||||||  Rybelsus (semaglutide oral) / Novo Nordisk
    Journal, Real-world evidence, Real-world effectiveness, Real-world:  Real world effectiveness of oral semaglutide: Focus on patients with type 2 diabetes older than 75?years. (Pubmed Central) -  Dec 12, 2024   
    The present real-world study suggests that persistence is significantly lower when semaglutide is administered as a once-daily tablet compared with a weekly injection, while there are no differences in efficacy between the two formulations. In our study, OS results efficacy in non-elderly and elderly patients, making it an effective treatment option also for very elderly type 2 diabetic patients.
  • ||||||||||  Rybelsus (semaglutide oral) / Novo Nordisk
    Retrospective data, Journal, Real-world evidence, Patient reported outcomes, Real-world:  Oral Semaglutide Use in Type (Pubmed Central) -  Nov 14, 2024   
    P
    The PIONEER REAL pooled analysis shows that people initiating oral semaglutide treatment experience improved glycemic control and body weight loss across age groups and T2D duration. This occurs regardless of specialist or primary care practice setting and is accompanied by an increased treatment satisfaction.
  • ||||||||||  Rybelsus (semaglutide oral) / Novo Nordisk
    Economic Impact of Modern Oral Antidiabetic Drugs: A Cost-Utility Analysis () -  Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_2912;    
    OBJECTIVES: To assess the cost-utility of oral semaglutide (14 mg once daily) versus dipeptidyl peptidase-4 inhibitors (DPP4i), sodium-glucose cotransporter-2 inhibitors (iSGLT2) and the combination SGLT2i + DPP4i for the treatment of Type 2 Diabetes (T2D) patients who cannot be controlled with metformin monotherapy in the Colombian health system. The results of this analysis suggest that, from an economic and health outcomes point of view, oral semaglutide (14 mg once daily) should be considered as a cost-effective alternative for the treatment of Type 2 Diabetes patients in the Colombian health system.
  • ||||||||||  Victoza (liraglutide) / Novo Nordisk, Rybelsus (semaglutide oral) / Novo Nordisk
    Journal:  Impact of Manufacturing Process and Compounding on Properties and Quality of Follow-On GLP-1 Polypeptide Drugs. (Pubmed Central) -  Nov 1, 2024   
    This study highlights that differences in the manufacturing processes of follow-on semaglutide and liraglutide (vs those used for originators) can result in several changes to the DSs and DPs. The impact of these changes on efficacy and safety outcomes remains unknown and should be investigated by clinical studies.
  • ||||||||||  Rybelsus (semaglutide oral) / Novo Nordisk
    Journal:  Food-induced small bowel obstruction observed in a patient with inappropriate use of semaglutide. (Pubmed Central) -  Oct 29, 2024   
    She started taking an oral semaglutide, a GLP1-RA, and it was soon switched to weekly subcutaneous semaglutide because of ineffectiveness...For example, the package inserts in Japan do not mention intestinal obstruction. We hope that the present report will prove helpful in paying attention to GLP1-RAs as a factor in bowel obstruction, including FIBO.
  • ||||||||||  Rybelsus (semaglutide oral) / Novo Nordisk
    Review, Journal:  Peptide GLP-1 receptor agonists: From injection to oral delivery strategies. (Pubmed Central) -  Oct 26, 2024   
    Apart from oral semaglutide, which does not require injection, other peptide GLP-1RAs need to be subcutaneously administered...Thus, it is imperative that advanced oral strategies for peptide GLP-1RAs need to be explored. This review mainly compares the current advantages and disadvantages of various oral delivery strategies for peptide GLP-1RAs in the developmental stage and discusses the latest research progress of peptide GLP-1RAs, providing a useful guide for the development of new oral peptide GLP-1RA drugs.
  • ||||||||||  Rybelsus (semaglutide oral) / Novo Nordisk
    Journal, Real-world evidence, Real-world:  Real-world use of oral versus subcutaneous semaglutide in a cohort of type 2 diabetic patients: which option to which patient? (Pubmed Central) -  Oct 14, 2024   
    In our experience, injectable semaglutide is preferred in patients with excess weight and shorter disease duration, while the oral formulation was used later and especially after therapeutic failure of previous therapies. Follow-up data indicate similar tolerability and efficacy of both formulations, despite subcutaneous semaglutide demonstrated greater efficacy.
  • ||||||||||  Rybelsus (semaglutide oral) / Novo Nordisk
    Journal:  Sodium glycocholate liposome encapsulated semaglutide increases oral bioavailability by promoting intestinal absorption. (Pubmed Central) -  Oct 9, 2024   
    SGC-Lip enhances the absorption of semaglutide in the small intestinal villi via an apical sodium-dependent bile acid transporter (ASBT)-mediated pathway with the highest penetration at the ileal site. In summary, the oral bioavailability of semaglutide can be improved by encapsulating semaglutide in SGC-Lip and utilizing the stabilizing and permeation-promoting effects of SGC on liposomes.
  • ||||||||||  Rybelsus (semaglutide oral) / Novo Nordisk
    Preclinical, Journal:  Bioengineered Nanomedicines Targeting the Intestinal Fc Receptor Achieve the Improved Glucoregulatory Effect of Semaglutide in a Type 2 Diabetic Mice Model. (Pubmed Central) -  Oct 2, 2024   
    The encapsulation of semaglutide into FcRn-targeted NPs was translated in an improved glucoregulatory effect in T2DM-induced mice when compared to the oral free semaglutide or nontargeted NP groups, after daily oral administrations for 7 days...The biodistribution of fluorescently labeled NPs through the gastrointestinal tract demonstrated that the nanosystems targeting the hFcRn are retained longer in the ileum and colorectum, where the expression of FcRn is more prevalent, than nontargeted NPs. Therefore, FcRn-targeted nanocarriers proved to be an effective platform for improving the pharmacological effect of semaglutide in a T2DM-induced mice model.
  • ||||||||||  Rybelsus (semaglutide oral) / Novo Nordisk
    Enrollment open:  The GAPSID Study - How GLP-1 Analogues Prevent Steroid-Induced Diabetes (clinicaltrials.gov) -  Oct 1, 2024   
    P=N/A,  N=60, Recruiting, 
    Therefore, FcRn-targeted nanocarriers proved to be an effective platform for improving the pharmacological effect of semaglutide in a T2DM-induced mice model. Not yet recruiting --> Recruiting
  • ||||||||||  Rybelsus (semaglutide oral) / Novo Nordisk
    Effect of Semaglutide in an Ischemic AKI Model (Exhibit Hall, Convention Center) -  Sep 23, 2024 - Abstract #KIDNEYWEEK2024KIDNEY_WEEK_3539;    
    Objectives: To evaluate the effect of oral semaglutide on the renal function of rats subjected to an animal model of ischemia/reperfusion This is an experimental study with adult male Wistar rats, weighing 250-300g, planned in groups: SHAM(control, with simulated clamping of the renal pedicle); GLP-1(semaglutide, oral; 3mg/day; 5 days); Ischemia and Reperfusion (IR)(clamping of bilateral renal pedicles for 30 minutes, followed by reperfusion) and GLP-1+IR(semaglutide followed by IR). Semaglutide showed a renoprotective effect associated with its antioxidant role that prevented the reduction in renal function caused by ischemic AKI.